

Organised by

**LE STUDIUM**  
Loire Valley  
Institute for Advanced Studies

# ISyCatC V

**THERAPEUTIC  
TARGETING OF  
CATHEPSIN C**FROM PATHOPHYSIOLOGY  
TO TREATMENT

# ISyCatC V

*In Memory of Prof. Carl-Bertil Laurel*

With the support of

**Contact / website**✉ [brice.korkmaz@inserm.fr](mailto:brice.korkmaz@inserm.fr)🌐 [isycatc26.sciencesconf.org](http://isycatc26.sciencesconf.org)**PROGRAM**  
15 > 17 APRIL 2026  
TOURS, FRANCE**Symposium Venue**Hôtel de Ville (Tours City Hall)  
Place de la Liberté 37000 ToursHôtel Oceania L'Univers Tours  
5 Bd Heurteloup 37000 Tours

**Chair:** Dr Brice Korkmaz  
**Scientific committee:** Prof. Gilles Lalmanach,  
Prof. Rita Vanbever, Dr Aurélien Montagu,  
Prof. Lars Hellman, Prof. Artur Gieldon,  
Prof. Guillaume Médard  
**Organization Committee:** Lada Sabirova,  
Dr. Thibault Chazeirat, Anne-Sophie Venet Charles

## Wednesday April 15<sup>th</sup>

Tours City Hall

19:00 Welcome cocktail reception

### 20:00 OPENING AND WELCOME SPEECH

**Brice Korkmaz** [France]

- The past, present and future of pharmacological targeting of cathepsin C

**Représentant** Région Centre Val-de-Loire [France]

*Fonction du représentant*

**Daniel Alquier** Université de Tours [France]

*Vice-président en charge de la recherche*

**Paola De Carli** Vaincre la Mucoviscidose [France]

*Scientific Director*

**Daniel Sojka** International Proteolysis Society [Czech Republic]

*IPS Council member*

- Prof. Carl-Bertil Laurell's biography by **Robert Stockley** [UK]

### Award ceremony

### 20:30 KEYNOTE LECTURE

**James D. Chalmers** [UK]

- Targeting cathepsin C: latest clinical advances

*Presentation on clinical trial results and disease mechanisms, followed by a discussion on pathophysiology and therapeutic approaches*

## Thursday April 16<sup>th</sup>

Hotel Océania | Room Eugénie

08:30 Registration

### 09:00 Session 1

#### PATHOPHYSIOLOGY OF CATHEPSIN C

Chair: G. Lalmanach [France]

09:00 **M. Novinec** [Slovenia]

- Oligomeric composition and dynamics of human cathepsin C

09:20 **P. Eickholz** [Germany]

- How does Papillon-Lefèvre syndrom look?

09:40 **A. Gilmour** [UK]

- Cathepsin C activity in pleural infection

10:00 **G. Médard** [Greece]

- Chemoproteomics for characterization of NSPs-AAP-1

### 10:25 | 11:00 Coffee break

11:00 **D. Sojka** [Czech Republic]

- Cathepsin C-type dipeptidyl peptidases in blood-feeding parasites: emerging roles and therapeutic opportunities

11:20 **C. Taggart** [UK]

- Pharmacological inhibition of cathepsin S and consequences for cathepsin C maturation and myeloid cell function

11:40 *Selected 5 min Talk:*

- C. Hughes** [UK]: *Cathepsin C activity in the airway inflammation*

### 11:50 Session 2

#### PATHOPHYSIOLOGY OF CATHEPSIN C TARGETS

Chair: G. Kwapiszewska [Austria]

11:50 **P. McDonald** [Canada]

- A wider-ranging inhibition of cathepsin C and of its substrates in inflammation

12:10 **M. Sienczyk** [Poland]

- Neutrophil serine proteases targeted by various phosphonates - the good and not that bad

### 12:30 | 14:30 Lunch Buffet

14:30 **M. Selsted** [USA]

- Unexpected role of cathepsin C in the biosynthetic maturation of alpha- and theta-defensins

14:50 **L. Sabirova** [France]

- Differential proteolytic processing, stability, and activation of neutrophil serine proteases in human myelomonocytic cells

15:10 **M. Mall** [Germany]

- Neutrophil serine proteases in cystic fibrosis: role in disease pathogenesis and rationale as therapeutic target

15:30 *Selected 5 min Talk:*

- T. Chazeirat** [France]: *Quantification of neutrophil serine proteases in bronchiectasis*

15:35 **C.H. Chen** [UK]

- Investigating pharmacological inhibition of cathepsin S on human macrophage function and its potential as a target for alpha-1 antitrypsin deficiency

### 15:55 | 16:30 Coffee break

16:30 **A. Ö. Yildirim** [Germany]

- Neutrophil serine proteases in bronchiolitis obliterans syndrome

16:50 **M. Wegmann** [Germany]

- New therapeutic targets in neutrophil asthma

17:10 **R. Vanbever** [Belgium]

- A single-domain antibody better protects the lung tissue against neutrophil elastase-mediated damage than alpha-1-antitrypsin

### 20:00 Dinner

## Friday April 17<sup>th</sup>

Hotel Océania | Room Rockefeller

### 09:00 Session 3

#### PHARMACOLOGICAL TARGETING OF CATHEPSIN C

Chairs: L. Hellman [Sweden] & A. Geldon [Poland]

09:00 **J.D. Chalmers** [UK]

- Cathepsin C inhibition using BI 1291583 in adults with bronchiectasis: AIRLEAF, a phase II randomised, double-blind, placebo-controlled, dose-finding study

09:20 **V. Sutton** [Australia]

- Pharmacologic inhibition of cathepsin C in CD8T or NK cells

09:40 *Selected 5 min Talk:*

- R. Domain** [Luxembourg]: *Alternative cathepsin C-independent pathways for granzyme zymogen maturation in cytotoxic lymphocytes*

09:50 **M. Long** [UK]

- Investigating the impact of DPP1/Cathepsin C or direct neutrophil elastase inhibition in humans using multiomics

### 10:10 | 11:00 Coffee break

11:00 **M. Rhimi** [France]

- Inactivation of cathepsin C in inflammatory bowel diseases

11:20 **I. Borek** [Austria]

- Inactivation of cathepsin C in pulmonary arterial hypertension

11:40 **Y. Terada** [Japan]

- Pharmacological targeting of cathepsin C in rat model of ANCA-vasculitis

12:00 **K.J. Chen** [USA]

- In vivo* evaluation of novel cathepsin C inhibitors across preclinical models of inflammatory diseases

### 12:30 | 14:30 Lunch Buffet

14:30 **B. Liu** [Germany]

- Pharmacological inhibition of the cysteine protease cathepsin C on non-renal vasculature in a rat model of polycystic kidney disease

14:50 **A. Shoemark** [UK]

- Investigating the impact of cathepsin C inhibition on azurocidin

15:10 **E. Johnson** [UK]

- Broad immunomodulatory effects of the cathepsin C inhibitor, brensocatib in bronchiectasis: Data from the Phase 2, double-blind, placebo-controlled WILLOW Trial

15:30 **J. Cichy** [Poland]

- Targeting cathepsin C in neutrophil differentiation and function

15:50 *Selected 5 min Talk:*

- A. Kutlu** [Turkey]: *Dual targeting of cathepsin C and S in COPD: design and evaluation of novel cathepsin S inhibitors*

### 15:55 | 16:15 Coffee break

### 16:15 CONCLUDING REMARKS & FUTURE PERSPECTIVES

**B. Korkmaz** [France]

20:00 Dinner Gala - Tours City Hall